纳洛酮市场按强度、给药途径、分销管道和地区划分

2025 年全球纳洛酮市场规模估计为 14.838 亿美元，预计到 2032 年将达到 30.057 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 10.6%。

数字。 2025 年纳洛酮各地区市场占有率（%）

纳洛酮是一种鸦片类药物拮抗剂，用于完全或部分逆转鸦片类药物过量摄取。它的工作原理是竞争性地与鸦片受体结合，逆转或阻断其他鸦片类药物的作用。纳洛酮已成为阿片类药物过量摄取紧急医疗的重要组成部分。全球许多地区正经历持续的鸦片类药物危机，阿片类药物滥用现象近期急剧增加。因此，对于紧急治疗所需的易获得的纳洛酮製剂的需求日益增加。预计这一因素将对未来几年全球纳洛酮市场的成长轨迹产生重大影响。

市场动态

全球纳洛酮市场主要受到全球阿片类药物过量摄取案例增加的推动。美国美国药物滥用实验室的数据显示，2000年至2020年间，美国阿片类药物过量摄取死亡率上升了130%以上。此外，新冠肺炎疫情加剧了社会隔离对心理健康的影响，导致许多国家阿片类药物滥用现象增加。医疗保健和执法机构对易于使用的纳洛酮输送製剂（如滴鼻剂和自动注射器）的需求很高，这推动了市场成长。然而，纳洛酮治疗的副作用和替代治疗方案的可用性限制了市场的扩张。正在进行的长效纳洛酮製剂研发将为未来的主要企业提供丰厚的机会。

研究的主要特点

• 本报告对全球纳洛酮市场进行了详细分析，并提供了预测期（2025-2032）的市场规模和年复合成长率（CAGR%），假设 2024 年为基准年。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
• 它根据公司亮点、产品系列、关键亮点、财务业绩和策略等参数，对全球纳洛酮市场的主要企业进行了概述。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员将透过全球纳洛酮市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场概况

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 波特的分析
• 产业趋势
• 流行病学
• 赎回情况
• 监管情景
• 产品发布和核准
• 收购和合作场景

4. 全球纳洛酮市场 - 冠状病毒 (COVID-19) 大流行的影响

• COVID-19 流行病学
• COVID-19 对纳洛酮供需的影响
• COVID-19 对整个医疗产业的影响

5. 全球纳洛酮市场，依实力划分，2020 年至 2032 年

• 介绍
• 2.0mg/ml
• 1mg/ml
• 0.4mg/ml
• 其他的

6. 2020 年至 2032 年按给药途径分類的全球纳洛酮市场

• 介绍
• 鼻腔内
• 注射
• 肌肉注射
• 皮下
• 静脉

7. 2020 年至 2032 年全球纳洛酮市场按分销管道划分

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年全球纳洛酮市场（按地区）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 非洲

第九章 竞争格局

• 公司简介
  • Viatris Inc.
  • Opiant Pharmaceuticals
  • Akorn Operating Company LLC
  • Pfizer, Inc.
  • Novartis AG
  • Indivior Plc.
  • Emergent BioSolutions Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Kern Pharma, SL
  • Hikma Pharmaceuticals PLC
  • Mundipharma International Limited
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

第 10 章 分析师观点

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Naloxone Market is estimated to be valued at USD 1,483.8 Mn in 2025 and is expected to reach USD 3,005.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.

Figure. Naloxone Market Share (%), By Region 2025

Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.

Market Dynamics:

The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2020. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.

Key Features of the Study:

• This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.

Market Segmentation

• Strength:
  • 2.0 mg/ml
  • 1 mg/ml
  • 0.4 mg/ml
  • Others
• Route of Administration:
  • Intranasal
  • Injectable
  • Intramuscular
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • EMERGENT
  • Indivior PLC
  • Akorn, Inc
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Sandoz
  • Teva Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Naloxone Market, By Strength
  • Naloxone Market, By Route of Administration
  • Naloxone Market, By Distribution Channel
  • Naloxone Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Impact of COVID-19 on the Demand and Supply of Naloxone
• Impact of COVID-19 on the Overall Healthcare Sector

5. Global Naloxone Market, By Strength, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• 2.0 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 1mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 0.4 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

6. Global Naloxone Market, By Route of Administration, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Intramuscular
• Subcutaneous
• Intravenous

7. Global Naloxone Market, By Distribution Channel, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

8. Global Naloxone Market, By Region, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country/Region, 2020-2032 (USD MN)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

• Company Profiles
  • Viatris Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Opiant Pharmaceuticals
  • Akorn Operating Company LLC
  • Pfizer, Inc.
  • Novartis AG
  • Indivior Plc.
  • Emergent BioSolutions Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Kern Pharma, S.L.
  • Hikma Pharmaceuticals PLC
  • Mundipharma International Limited
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact